MGI and Karolinska's Centre for Translational Microbiome Research will work together to investigate the role of the microbiome in human health.
The complaint, filed yesterday, alleges that Illumina's two-channel sequencing systems infringe Complete Genomics' US Patent No. 9,222,132.
The lawsuit follows a similar one that Illumina filed earlier this year in Germany against Latvia MGI Tech, another subsidiary of BGI Group.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
Both teams had sequencing data generated at BGI and said that going forward, it would be important to validate the technology outside of BGI.
The suit alleges that BGI's sequencing products and reagents infringe a European patent held by Illumina.
At the AGBT conference, MGI Tech showcased its technologies, while a Sanger Institute researcher presented results from a comparison between BGI and Illumina data.
The Shenzhen, China-based BGI subsidiary plans to expand its business to the United Arab Emirates, Qatar, Saudi Arabia, and other countries.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.